Stock traders are known for their occasional love of aphorisms, and some easily come to mind. “Buy low, sell high” and “Don’t try to time the market” are two that have stood the test of time, and while they may sound contradictory, they don’t necessarily. It is possible to buy cheaply even in an uptrend. Checking with Wall Street analysts to see if fundamentals are solid can provide clues as to whether a stock pull-out is just a passing event. The analysts make a name for themselves by finding these opportunities and making us aware of them. With that in mind, we used the TipRanks database to search for three stocks that have seen this decline recently – and that analysts say have a lot of upside potential. Let’s take a look at the details. Cardiff Oncology (CRDF) The first stock we look at, Cardiff Oncology, is a clinical-stage biopharma company with a laser focus on cancer treatment. In particular, the company is focused on developing medication options for cancer patients whose current treatment has become less effective. Cardiff is developing Onvansertib, a world-class, third-generation Polo-like kinase 1 (PLK1) inhibitor that has been developed in combination with existing drugs to overcome treatment resistance, improve patient response and increase survival rates. Cardiff’s current research pipeline includes onvansertib in three separate clinical programs in combination with various existing drugs to fight three different types of cancer. The programs are a phase 1b clinical trial of Onvansertib plus Folfiri / Avastin for the treatment of KRAS-mutated metastatic colorectal cancer (mCRC) and two phase 2 studies, one in combination with Zytiga for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and one for the treatment of relapsed / refractory acute myeloid leukemia (AML) in combination with decitabine. Preliminary data for these studies show positive responses to onvansertib in combination with existing therapies. In the mCRC program, 86% of the evaluable patients showed a clinical benefit, while in the mCRPC program 54% of the patients in three cohorts showed a radiologically stable disease. In the AML program, 20% of patients achieved complete remission. These early data are believed to be significant and the company plans to initiate further trials later this year. That backdrop, and the stock’s 50% year-to-date decline, caught the attention of Maxim Group’s 5-star analyst Jason McCarthy. McCarthy points out that stocks have recently declined on the back of profit-taking and more general market changes. “While valuation has declined since hitting a 52-week high in late fourth quarter, CRDF is not alone from a KRAS perspective … and we see Cardiff as the potentially more attractive asset in mCRC, which continues to be backed with emerging data. We’re still seeing a KRAS area that will continue to be active and of potentially great value given the unmet need, a well-funded business in Cardiff ($ 130 million in cash from YE20) and a drug in Onvansertib multiple options. Taken together, we see this as an opportunity to buy CRDF stock because of its weakness, “said McCarthy. McCarthy gives CRDF a buy rating, and his target price of $ 30 implies a robust uptrend of 242% from current levels. (To McCarthy’s track record, too Watch, Click Here) Overall, this stock has a consensus analyst rating with a strong buy, and that verdict is unanimous based on 3 recent positive ratings. The stock is selling for $ 8.76 and its average price target of $ 27.33 drops Close a 212% appreciation this year (See CRDF stock analysis on TipRanks) MicroStrategy (MSTR) When it comes to switching we’re going to be looking at high tech. In particular, we’re going to look at the world’s largest independent business intelligence company, MicroStrategy. $ 3 billion company offers a winning combination With modern analytics, a comprehensive company platform and optimization options for the cloud and on-site. MicroStrategy products enable customers to make smarter, faster decisions – a key advantage in today’s high-speed business rld. MicroStrategy stocks peaked over $ 1,200 in early February this year and have since declined 53%. The decline in stocks also comes after the company doubled its exposure to Bitcoin. Management started buying the cryptocurrency as a store of value and investment last August. MicroStrategy now holds more than $ 4.4 billion in BTC. The value of the crypto coin has more than quadrupled since MicroStrategy began making purchases. In a research report titled “Pullback Offers Attractive Entry Point,” BTIG’s 5-star analyst Mark Palmer names two tracks for the company’s success. First of all, “[We] believe that MSTR’s acquisition of Bitcoin as the primary treasury reserve asset is a rational move aimed at protecting the company’s inherent value over the long term. At the same time, the MSTR strategy allows one to capture the benefits of the increasing adoption of cryptocurrency by institutional investors concerned about increasing inflationary pressures. Second, Palmer adds, “While most of the attention given MSTR has been on introducing Bitcoin as its primary treasury asset, we believe the company has an attractive business analytics software game in particular when the company goes through a shift from a product licensing model to a cloud-first SaaS subscription model with mobile offerings. “To this end, Palmer, along with its Buy Rating, sets a price target of USD 850 for one year on MSTG shares. At the current level, this price target implies an upward movement of 42%. (To see Palmer’s track record, click here.) MicroStrategy’s controversial Bitcoin policy has sparked some divisions among Wall Street analysts, as recent valuations show – the buy / hold / sell down 2 to 1 to 1 falling off. This gives the stock a consensus rating for analysts with a moderate buy. The shares sell for $ 601.27, and their average price target of $ 698.75 represents an uptrend of 16% for the year ahead. (See MSTR stock analysis on TipRanks.) Roku (ROKU) Let’s stay in the tech world, but let’s look at online TV streaming. Roku is known as a leader in this growing niche, where it pioneered video-on-demand with its streaming player of the same name. The Roku player connects to the user’s television and the company offers connected streaming services. At the end of Roku, the profits come from a combination of audience monetization and advertiser engagement. Roku stock has fallen 25% since its most recent high in February this year. But even after recent losses, the stock is still up 184% over the past 12 months. Profits reflect Roku’s successes in 2020: Revenue increased 58% year over year to $ 1.778 billion; 14.3 million new active accounts increased customer roles to 51.2 million; and 38% of all smart TVs sold in the U.S. in 2020 were Roku models. In March of this year, Roku made two major acquisitions, adding the popular franchise “This Old House” to its content offering, and partnering with Nielsen Holdings on ad and content measurement and video advertising. These steps came after Roku acquired the rights to Quibi’s content library in January, which has now been renamed “Roku Originals”. While Roku is a content streamer – and rightly focused on expanding its content offering – it’s also a tech company with an innovation-focused tech company. Earlier this month, Roku announced a new customer package that includes a voice-activated TV remote control with a rechargeable battery, hands-free functionality and an audible remote control finder. It is a technical device that is sure to be appreciated by the customer. So Roku is taking the steps expected of a tech-driven content streaming company. However, Deutsche Bank analyst Jeffrey Rand sees advertising as the company’s main path. “As ad revenue continues to grow as a mix of revenue, we expect Roku to continue focusing its strategy on expanding its influence in the ad market. The acquisition of Nielsen’s Advanced Video Advertising (AVA) business gives Roku the opportunity to enter the linear television advertising market. We anticipate Roku will continue to seek, organically and inorganically, investing in ways to expand its role in the advertising market for both streaming and linear television, ”said Rand. On balance, Rand sums up Roku as a solid choice for investors looking for a relative bargain: “While many growth-oriented tech companies have faced challenges in the current environment and the transition to streaming is fast-moving, we see the Roku stock’s recent retreat as good buying opportunity. “Consistent with this bullish outlook, Rand is giving ROKU a buy rating and his target price of $ 500 indicates an upward movement of 43% over the next 12 months. (To see Rand’s track record, click here.) So there’s the Deutsche Bank view, but what does the rest of the Analyst Brotherhood think? All in all, the road maintains a positive, if somewhat more reserved, attitude. Based on 20 analysts recorded in the last 3 months, 14 rate ROKU as a buy, 5 as a hold and only 1 as a sale. The 12-month average price target is $ 476.95, up ~ 36% from current levels. (See ROKU stock analysis on TipRanks.) To find great ideas for trading stocks at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.